Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Lupus Survival Is Improving Slowly

Will Boggs, MD  |  October 30, 2017

NEW YORK (Reuters Health)—Systemic lupus erythematosus (SLE) mortality has declined during the past 46 years in the U.S.—but more slowly than mortality in the general population, according to a nationwide study. “Based on our experience in the clinic and according to previous reports showing improvement in the short-term (five- to 10-year) survival in lupus, I…

Obamacare Benchmark Premiums Up 37% in 2018 after Subsidy Cut-Off

Michael Erman  |  October 30, 2017

NEW YORK (Reuters)—The average monthly premium for benchmark Obamacare insurance plans will surge around 37% in 2018, the U.S. Department of Health and Human Services said on Monday, fueled by the Trump administration’s suspension of billions of dollars in subsidy payments to health insurers. The average monthly premium for the second-lowest cost “silver” plan for…

Varus Thrust Is Associated with Progressive Knee OA

Arthritis & Rheumatology  |  October 30, 2017

To determine if varus thrust, a bowing out of the knee during gait (i.e., the first appearance or worsening of varus alignment during stance), is associated with incident and progressive knee osteoarthritis (OA), these researchers undertook an Osteoarthritis Initiative ancillary study. They also considered hypothesized associations adjusted for static alignment, anticipating some attenuation. Methods: Gait…

Tocilizumab a “First Choice” for PHID Syndrome

Reuters Staff  |  October 30, 2017

NEW YORK (Reuters Health)—Tocilizumab should be the “first choice” for treatment of the autoinflammatory and cutaneous manifestations of pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome, say clinicians from the U.K. PHID syndrome is an extremely rare autosomal recessive genetic disease caused by mutations in the SLC29A3 gene. Children with the syndrome develop patches…

Insights into the Metabolic Control of RA T Cells

Lara C. Pullen, PhD  |  October 30, 2017

Metabolic control of T cell locomotion provides new opportunities to interfere with T cell invasion into specific tissue sites, according to new research…

Judge Rejects Bid by 18 U.S. States to Revive Obamacare Subsidies

Dan Levine and Lawrence Hurley  |  October 27, 2017

SAN FRANCISCO/WASHINGTON (Reuters)—A U.S. judge on Wednesday refused to block President Donald Trump’s decision to end subsidy payments to health insurers under Obamacare, handing Trump a victory against Democratic attorneys general who have regularly challenged the president’s policies in court. U.S. District Judge Vince Chhabria in San Francisco said the federal government did not have…

Americans Want to See a Bipartisan Fix for Obamacare

Jilian Mincer and Chris Kahn  |  October 27, 2017

NEW YORK (Reuters)—As Republican and Democratic lawmakers clash over the future of Obamacare, Americans largely are eager for a bipartisan solution to its shortcomings, according to a Reuters/Ipsos opinion poll released on Thursday. The Oct. 14-23 poll found that 62 percent of Americans want former President Barack Obama’s healthcare law to be maintained, up from…

Billionaire Insys Founder Charged in U.S. Opioid Bribe Case

Nate Raymond  |  October 27, 2017

BOSTON (Reuters)—The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic. John Kapoor, Insys’ majority shareholder who stepped down as chief executive in January, was charged…

Trump Declares Opioids a U.S. Public Health Emergency

Yasmeen Abutaleb and Jeff Mason  |  October 27, 2017

WASHINGTON (Reuters)—U.S. President Donald Trump declared the opioid crisis a public health emergency on Thursday, stopping short of a national emergency declaration he promised months ago that would have freed up more federal money. Responding to a growing problem wreaking havoc in rural areas, Trump’s declaration will redirect federal resources and loosen regulations to combat…

FDA Sets Stricter Requirements for Immediate-Release Opioids to Prevent Misuse & Abuse

Michele B. Kaufman, PharmD, BCGP  |  October 27, 2017

The FDA is expanding its Risk Evaluation and Mitigation Strategy (REMS) to include manufacturers of immediate-release opioids. The makers of these drugs will soon be required to provide training and education to healthcare professionals on the proper prescription and use of the drugs for pain management…

  • « Previous Page
  • 1
  • …
  • 384
  • 385
  • 386
  • 387
  • 388
  • …
  • 814
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences